I agree completely. I firmly contend that LL will be a companion therapy as well as first line therapy for many many disease states.

I know this is a wild idea but I can't help thinking LL will be OTC due to it's safety, efficacy and tolerability profile once it's MOA's are completely understood, meaning it will have many more MOA's than what we already know. JMHO. GLTA